Skip to main content
SpringerLink
Log in

Valdecoxib

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ In ten large, well-controlled, randomised trials (n = 203 to 1089), valdecoxib, a selective inhibitor of cyclo-oxygenase-2, was significantly more effective than placebo in the treatment of osteoarthritis, rheumatoid arthritis and pain associated with primary dysmenorrhoea, and for postsurgical analgesia.

  • ▴ Valdecoxib 1.25 to 10mg twice daily and valdecoxib 10mg once daily were more effective than placebo for the relief of pain in patients with osteoarthritis of the knee, and dosages above 5mg twice daily were similar in efficacy to naproxen 500mg twice daily. Similarly, valdecoxib 5 and 10 mg/day were as effective far osteoarthritis of the hip as naproxen 500mg twice daily.

  • ▴ In patients with rheumatoid arthritis, valdecoxib 10, 20 or 40 mg/day was significantly more effective than placebo, and similar in efficacy to naproxen 500mg twice daily; there were no significant differences in efficacy between the three dosages of valdecoxib.

  • ▴ Valdecoxib 20 or 40mg administered 1 to 3 hours before and 12, 24 and 36 hours after hip arthroplasty provided significantly better analgesia than placebo, and significantly reduced the amount of morphine taken by patients.

  • ▴ Single doses of valdecoxib 10 to 80mg administered before foot or oral surgery provided significantly better analgesia than placebo; when administered after oral surgery, valdecoxib 20 or 40mg provided greater sustained analgesia than oxycodone 10mg/paracetamol 1000mg or rofecoxib 50mg.

  • ▴ In contrast to three nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), valdecoxib 40mg twice daily did not cause significant changes in platelet function and bleeding times.

  • ▴ Chronic users of NSAIDs who were switched to valdecoxib 10 or 20 mg/day for 12 weeks experienced significantly fewer gastroduodenal erosions or ulcers than patients receiving ibuprofen 2400 mg/day or diclofenac 150 mg/day for 12 weeks.

  • ▴ Valdecoxib was generally well tolerated in clinical trials, with a similar incidence of adverse events to placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig 7
Fig. 8

Similar content being viewed by others

References

  1. Adams EH, Hunter TS, Williams T. New options in the treatment of arthritis. J Manage Care Pharm 1999 Sep 31; 5: 443–8

    Google Scholar 

  2. Carr DB, Goudas LC. Acute Pain. Lancet 1999 Jun 12; 353: 2051–8

    Article  PubMed  CAS  Google Scholar 

  3. Botting JH. Nonsteroidal antiinflammatory agents. Drugs Today 1999 Apr; 35: 225–35

    PubMed  CAS  Google Scholar 

  4. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61(8): 1133–41; discussion 1142-3

    Article  PubMed  CAS  Google Scholar 

  5. Fiechtner JJ, Sikes D, Recker D. A double-blind, placebo-controlled dose ranging study to evaluate the efficacy of valdecoxib, a novel COX-2 specific inhibitor, in treating the signs and symptoms of osteoarthritis of the knee [abstract no. OP0048]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic

  6. Daniels SE, Talwalker S, Hubbard RC, et al. Pre-operative valdecoxib, a COX-2 specific inhibitor, provides effective and long lasting pain relief following oral surgery [abstract no. A-810]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.

  7. Dejardins PJ, Talwalker S, Hubbard RC, et al. Pre-operative administration of valdecoxib, a potent COX-2 specific inhibitor, provides effective post-operative analgesia [abstract no. A-811]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana

  8. Camu F, Beecher T, Recker DP, et al. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002 Jan 28; 9(1): 43–51

    Article  PubMed  Google Scholar 

  9. Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-pheny-lisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX- 2. J Med Chem 2000 Mar 9; 43(5): 775–7

    Article  PubMed  CAS  Google Scholar 

  10. Leese PT, Recker D, Kuss ME. The novel COX-2 specific inhibitor, valdecoxib, does not affect platelet function in healthy adults [abstract no. 043]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic.

  11. Leese PT, Recker D, Kuss ME. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 specific inhibitor, on platelet function in the elderly [abstract no. 042]. European Congress of Rheumatology; 2001 June 13–16; Prague, Czech Republic.

  12. Pharmacia Corporation. Bextra, valdecoxib tablets. Product information [online]. Available from URL: http://www.pnu.com [Accessed 2002 Aug 12]

  13. Kharasch E, Ibrahim A, Karim A, et al. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the pharmacokinetics and clinical effects of fentanyl and alfentanil [abstract no. A-450]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.

  14. Noroian G, Clive D. Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Drug Saf 2002; 25(3): 165–72

    Article  PubMed  CAS  Google Scholar 

  15. Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002 Jun;51(6):530–7

    PubMed  Google Scholar 

  16. Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002 Apr; 10(4): 290–6

    Article  PubMed  CAS  Google Scholar 

  17. Bensen W, Weaver A, Espinoza L, et al. Valdecoxib, a new COX-2 specific inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis [abstractno. 1896]. Arthritis Rheum 2001; 44 (9 Suppl.): 369

    Google Scholar 

  18. Daniels SE, Desjardins PJ, Talwalker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/ acetaminophen after oral surgery. J Am Dent Assoc 2002 May; 133(5): 611–21

    CAS  Google Scholar 

  19. Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002 Mar; 9(2): 89–97

    Article  PubMed  Google Scholar 

  20. Daniels DE, Torris S, Snabes MC. Efficacy of valdecoxib versus naproxen sodium in primary dysmenorrhea. Obstet Gynecol 2002; 99 Suppl.: 30S–1S

    Google Scholar 

  21. Camu F, Beecher T, Talwalker S, et al. The COX-2 specific inhibitor valdecoxib is opioid-sparing and provides effective analgesia in primary hip arthroplasty patients [abstract no. A-809]. American Society of Anesthesiologists; 2001 Oct 13–17; New Orleans, Louisiana.

  22. Goldstein JL, Fakouhi KM, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with valdecoxib compared to ibuprofen and diclofenac in patients with osteoarthritis: a multicenter trial [abstract no. 3032]. Gastroenterology 2001 Apr; 120 Suppl. 1: 597

    Google Scholar 

  23. Goldstein JL, Stenson W, Agrawal N, et al. Valdecoxib is associated with a significantly lower incidence of ulcer complications and symptomatic ulcers in arthritis patients as compared to NSAID. [abstract no. T1503] Gastroenterology2002 Apr; 122 Suppl. 1: A469

    Google Scholar 

  24. Goldstein JL, Kent J, Shu V, et al. Valdecoxib is less ulcerogenic than conventional NSAIDs in osteoarthritis (OA) and rheumatoid arthritis (RA) patients with high risk of peptic ulcer disease [abstract no. M1731]. Gastroenterology 2002 Apr; 122 Suppl. 1: A344

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 10, New Zealand

    Douglas Ormrod, Ken Wellington & Antona J. Wagstaff

Authors
  1. Douglas Ormrod
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken Wellington
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antona J. Wagstaff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken Wellington.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ormrod, D., Wellington, K. & Wagstaff, A.J. Valdecoxib. Drugs 62, 2059–2071 (2002). https://doi.org/10.2165/00003495-200262140-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262140-00005

Keywords

Search

Navigation